Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report

Oncologist. 2010;15(9):965-8. doi: 10.1634/theoncologist.2010-0118. Epub 2010 Aug 26.

Abstract

The use of rapamycin and thalidomide in a patient with metastatic gastroesophageal carcinoma, which led to disease stability associated with a significant tumor marker response and improved clinical quality of life, is reported.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Esophageal Neoplasms / drug therapy*
  • Esophagogastric Junction*
  • Humans
  • Male
  • Phosphorylation
  • Receptor, ErbB-2 / analysis
  • Sirolimus / administration & dosage
  • Stomach Neoplasms / drug therapy*
  • TOR Serine-Threonine Kinases / metabolism
  • Thalidomide / administration & dosage

Substances

  • Thalidomide
  • MTOR protein, human
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • TOR Serine-Threonine Kinases
  • Sirolimus